Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Geron Corporation    GERN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/11/2017 08/14/2017 08/15/2017 08/16/2017 08/17/2017 Date
2.08(c) 2.06(c) 2.05(c) 2.04(c) 2.06(c) Last
1 094 927 890 942 793 825 592 509 976 707 Volume
-0.48% -0.96% -0.49% -0.49% +0.98% Change
More quotes
Financials ($)
Sales 2017 1,25 M
EBIT 2017 -29,9 M
Net income 2017 -27,9 M
Debt 2017 -
Yield 2017 -
Sales 2018 31,0 M
EBIT 2018 -4,03 M
Net income 2018 -28,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 263x
Capi. / Sales2018 10,6x
Capitalization 328 M
More Financials
Company
Geron Corp. discovers and develops therapeutic products for cancer.It is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.Geron was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park,... 
More about the company
Surperformance© ratings of Geron Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on GERON CORPORATION
08/10 GERON CORPORATION (NASDAQ : GERN) reported earnings of ($0.04) per share beating..
08/09 GERON : reports 2Q loss
08/09 GERON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
08/09 GERON CORP : Results of Operations and Financial Condition, Financial Statements..
08/09 GERON CORPORATION : Reports Second Quarter 2017 Financial Results
08/01 GERON CORP : Other Events, Financial Statements and Exhibits (form 8-K)
08/01 Geron Announces Updates to Imetelstat Clinical Development
07/24 GERON CORP : Other Events (form 8-K)
07/24 GERON : Technical Snapshots for These Biotech Stocks -- Exelixis, Celldex Therap..
06/23 GERON CORPORATION : Today's Research Reports on Stocks to Watch: Geron Corporati..
More news
Sector news : Bio Therapeutic Drugs
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Bio Therapeutic Drugs
Latest Tweets
08/14Geron Corporation $GERN Earns Media Sentiment Score of 0.17  
08/10Geron's Imetelstat: Obstacles To Success  
08/10Geron Corporation Reports Second Quarter 2017 Financial Results -  
08/10Geron Corporation Reports Second Quarter 2017 Financial Results  
08/10$GERN: Geron beats by $0.01, misses on revs  
More tweets
Qtime:30
News from SeekingAlpha
08/10 GERON'S IMETELSTAT : Obstacles To Success
08/09 Geron beats by $0.01, misses on revenue
08/08 Notable earnings after Wednesday?s close
08/02 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
08/02 BIOTECH FORUM DAILY DIGEST : Revisiting Tetraphase Pharmaceuticals
Chart GERON CORPORATION
Duration : Period :
Geron Corporation Technical Analysis Chart | GERN | US3741631036 | 4-Traders
Technical analysis trends GERON CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 3,75 $
Spread / Average Target 82%
EPS Revisions
Managers
NameTitle
John A. Scarlett President, Chief Executive Officer & Director
Ho Young Huh Chairman
Olivia K. Bloom Chief Financial Officer, Treasurer & Executive VP
Karin Eastham Independent Director
Robert Jay Spiegel Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GERON CORPORATION-1.45%328
AMGEN14.77%122 447
CELGENE CORPORATION10.22%99 812
GILEAD SCIENCES1.02%94 471
REGENERON PHARMACEUTICALS27.64%49 721
VERTEX PHARMACEUTICALS101.63%37 450